ArticleJournal of clinical laboratory analysis2020
A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Long non-coding RNA-based single and combination independent prognostic biomarkers for hepatocellular carcinoma.Discover oncology · 2025Review
- RP11-Derived Long Non-Coding RNAs in Hepatocellular Carcinoma: Hidden Treasures in Plain Sight.Oncology research · 2025Review
- Serum exosomal long noncoding RNA CRNDE as a prognostic biomarker for hepatocellular carcinoma.Journal of clinical laboratory analysis · 2021Article
- Artificial intelligence method to predict overall survival of hepatocellular carcinoma.Hepatology forum · 2021Article
- A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients.Journal of clinical laboratory analysis · 2020Article
- Systematic Construction and Validation of an RNA-Binding Protein-Associated Model for Prognosis Prediction in Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a common neoplasm located in the liver. Accumulating evidence has highlighted that long noncoding RNAs (lncRNAs) are correlated with the survival of HCC patients. This study focuses on finding a lncRNA signature to predict the prognostic risk of HCC patients.
methodsStatistical and machine learning analyses were conducted to analyze the lncRNA expression data and corresponding clinical data of 180 HCC patients collected from the public online Tanric and The Cancer Genome Atlas (TCGA) databases.
resultsFrom the training dataset, we obtained the four-lncRNA model comprising RP11-495K9.6, RP11-96O20.2, RP11-359K18.3, and LINC00556 which can divide HCC patients into two different groups with significantly different prognosis (n = 90, median 1.81, 95% confidence interval [CI]: 1.50-4.91 vs 8.56 years, 95% CI: 6.96-9.97, log-rank test P < .001). The test dataset confirmed the prognostic ability of the signature (n = 90, median 1.95, 95% CI: 1.14-4.08 vs 5.80 years, 95% CI: 3.11-6.82, log-rank test P = .007). Receiver operating characteristic curve displayed the better prediction efficiency of the four-lncRNA signature than the tumor/node/metastasis stage. Cox analysis showed the four-lncRNA signature was an independent predictor of HCC prognosis.
conclusionThe four-lncRNA signature can be used as an independent biomarker for HCC patients to predict the prognostic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.